Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/177059
Title: Genetically determined telomere length and multiple myeloma risk and outcome
Author: Giaccherini, Matteo
Macauda, Angelica
Orciuolo, Enrico
Rymko, Marcin
Gruenpeter, Karolina
Dumontet, Charles
Raźny, Malgorzata
Moreno Aguado, Víctor
Buda, Gabriele
Beider, Katia
Varkonyi, Judit
Avet-Loiseau, Hervé
Martínez López, Joaquín
Marques, Herlander
Watek, Marzena
Sarasquete, Maria Eugenia
Andersen, Vibeke
Karlin, Lionel
Suska, Anna
Kruszewski, Marcin
Abildgaard, Niels
Dudziński, Marek
Butrym, Aleksandra
Nagler, Arnold
Vangsted, Annette Juul
Kadar, Katalin
Waldemar, Tomczak
Jamroziak, Krzysztof
Jacobsen, Svend Erik Hove
Ebbesen, Lene Hyldahl
Taszner, Michał
Mazur, Grzegorz
Lesueur, Fabienne
Pelosini, Matteo
García Sanz, Ramon
Jurczyszyn, Artur
Demangel, Delphine
Reis, Rui Manuel
Iskierka-Jażdżewska, Elżbieta
Markiewicz, Miroslaw
Gemignani, Federica
Subocz, Edyta
Zawirska, Daria
Druzd-Sitek, Agnieszka
Stępień, Anna
Alonso Aguado, Maria Henar
Sainz, Juan
Canzian, Federico
Campa, Daniele
Keywords: Mieloma múltiple
Telòmer
Multiple myeloma
Telomere
Issue Date: 1-Apr-2021
Publisher: Springer Nature
Abstract: Telomeres are involved in processes like cellular growth, chromosomal stability, and proper segregation to daughter cells. Telomere length measured in leukocytes (LTL) has been investigated in different cancer types, including multiple myeloma (MM). However, LTL measurement is prone to heterogeneity due to sample handling and study design (retrospective vs. prospective). LTL is genetically determined; genome-wide association studies identified 11 SNPs that, combined in a score, can be used as a genetic instrument to measure LTL and evaluate its association with MM risk. This approach has been already successfully attempted in various cancer types but never in MM. We tested the "teloscore" in 2407 MM patients and 1741 controls from the International Multiple Myeloma rESEarch (IMMeNSE) consortium. We observed an increased risk for longer genetically determined telomere length (gdTL) (OR = 1.69; 95% CI 1.36-2.11; P = 2.97 x 10(-6) for highest vs. lowest quintile of the score). Furthermore, in a subset of 1376 MM patients we tested the relationship between the teloscore and MM patients survival, observing a better prognosis for longer gdTL compared with shorter gdTL (HR = 0.93; 95% CI 0.86-0.99; P = 0.049). In conclusion, we report convincing evidence that longer gdTL is a risk marker for MM risk, and that it is potentially involved in increasing MM survival.
Note: Reproducció del document publicat a: https://doi.org/10.1038/s41408-021-00462-y
It is part of: Blood Cancer Journal, 2021, vol. 11
URI: http://hdl.handle.net/2445/177059
Related resource: https://doi.org/10.1038/s41408-021-00462-y
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s41408-021-00462-y.pdf676.37 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons